Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 3.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 88,637 shares of the biotechnology company’s stock after selling 3,519 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in United Therapeutics were worth $52,560,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of UTHR. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
United Therapeutics Stock Performance
Shares of UTHR opened at $547.06 on Monday. The stock has a 50 day moving average of $556.70 and a 200 day moving average of $529.55. The company has a market capitalization of $23.22 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.80 and a beta of 0.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.
Analyst Upgrades and Downgrades
UTHR has been the subject of a number of recent research reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Royal Bank Of Canada raised their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $644.82.
Read Our Latest Report on UTHR
Insiders Place Their Bets
In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,894,849.68. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 584,043 shares of company stock worth $328,382,628 in the last three months. 8.60% of the stock is currently owned by corporate insiders.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
